Calla Chow
Critical Care Medicine · Orangeburg, SCNPI 1083083117
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 38.9% of the total. Reporting peaked in 2022 at $592 and has fallen 57.7% since, to $251 in 2025.
Across 59 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$504
- GSK$227
- Regeneron Healthcare Solutions, Inc.$132
- Inogen, Inc.$66
- Verona Pharma, Inc.$63
- Baxter Healthcare$44
- plus $262 from 10 others
What the payments were for
- Food & beverage$1,26397%
- Education$353%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $504 |
| GSK | 8 | $227 |
| Regeneron Healthcare Solutions, Inc. | 2 | $132 |
| Inogen, Inc. | 6 | $66 |
| Verona Pharma, Inc. | 4 | $63 |
| Baxter Healthcare | 3 | $44 |
| Boehringer Ingelheim | 2 | $41 |
| Insmed, Inc. | 2 | $35 |
| Conmed Corporation | 1 | $33 |
| Novo Nordisk | 1 | $33 |
| Viatris Specialty LLC | 2 | $31 |
| Nabriva Therapeutics, PLC | 1 | $23 |
| Sanofi | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Itamar Medical Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$151
- DUPIXENT$106
How this compares
$1,298 in reported general payments places this provider in the 60th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $213,684 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 294 | $208,485 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 161 | $123,831 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $16,830 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $13,635 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $11,744 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 358 | $10,418 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,065 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $4,900 |
| Roflumilast | 78 | $4,482 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $3,420 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $3,318 |
| Varenicline Tartrate | 13 | $1,072 |
| Montelukast Sodium | 128 | $817 |
| Azelastine Hcl | 16 | $378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $227 | $225,315338 claims |
| Boehringer IngelheimOfev, Combivent Respimat | $41 | $219,74928 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $504 | $149,210217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Orangeburg
- Charlton StrangeCharleston$205K
- William AlleyneRock Hill$199K
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Daniel HerrHilton Head Island$151K
- Hafez HayekConway$138K
- Nicholas FoxCharleston$88K
- Nasir AwanGreenville$54K
- Christopher GilbertCharleston$44K
- Ikenna OnyebuekeSpartanburg$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.